Published in J Biol Chem on October 25, 1993
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 3.16
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci U S A (2000) 2.70
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol (2003) 2.64
A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J Virol (1995) 2.35
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
An amphipathic peptide from the C-terminal region of the human immunodeficiency virus envelope glycoprotein causes pore formation in membranes. J Virol (1994) 1.59
Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol (2004) 1.44
Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions. J Virol (2000) 1.38
Signal peptide fragments of preprolactin and HIV-1 p-gp160 interact with calmodulin. EMBO J (1997) 1.33
Viral calciomics: interplays between Ca2+ and virus. Cell Calcium (2009) 1.33
4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol (2007) 1.26
Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity. J Virol (2000) 1.21
Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Microbiol Rev (1996) 1.13
An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence. J Virol (2008) 1.13
Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J Virol (2005) 1.13
The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol (2012) 1.09
Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein. J Virol (1995) 1.08
HIV type 1 Gag as a target for antiviral therapy. AIDS Res Hum Retroviruses (2011) 1.08
The cytopathicity of a simian immunodeficiency virus Mne variant is determined by mutations in Gag and Env. J Virol (1997) 1.07
The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1. Cell Host Microbe (2012) 1.06
Envelope glycoprotein cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab acceptor. J Virol (2002) 1.05
Apoptosis induction by the binding of the carboxyl terminus of human immunodeficiency virus type 1 gp160 to calmodulin. J Virol (1998) 1.02
Binding of calmodulin to the HIV-1 matrix protein triggers myristate exposure. J Biol Chem (2010) 0.97
The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques. J Virol (2000) 0.96
C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. J Gen Virol (2012) 0.93
Protein engineering and NMR studies of calmodulin. Mol Cell Biochem (1996) 0.91
Properties of wild-type, C-terminally truncated, and chimeric maedi-visna virus glycoprotein and putative pseudotyping of retroviral vector particles. J Virol (2001) 0.90
The frantic play of the concealed HIV envelope cytoplasmic tail. Retrovirology (2013) 0.90
Role of the HIV-1 Matrix Protein in Gag Intracellular Trafficking and Targeting to the Plasma Membrane for Virus Assembly. Front Microbiol (2012) 0.87
Role of calmodulin in HIV-potentiated Fas-mediated apoptosis. Am J Pathol (1996) 0.86
NMR, biophysical, and biochemical studies reveal the minimal Calmodulin binding domain of the HIV-1 matrix protein. J Biol Chem (2011) 0.84
Point mutations in the C-terminus of HIV-1 gp160 reduce apoptosis and calmodulin binding without affecting viral replication. Virology (2005) 0.83
HIV protein sequence hotspots for crosstalk with host hub proteins. PLoS One (2011) 0.82
trans-dominant interference with human immunodeficiency virus type 1 replication and transmission in CD4(+) cells by an envelope double mutant. J Virol (1999) 0.82
Calmodulin binds a highly extended HIV-1 MA protein that refolds upon its release. Biophys J (2012) 0.82
Retroviral env glycoprotein trafficking and incorporation into virions. Mol Biol Int (2012) 0.80
Calcineurin-dependent mitochondrial disturbances in calcium-induced apoptosis of human immunodeficiency virus gp160-expressing CD4+ cells. J Virol (2002) 0.80
A leucine zipper motif in the cytoplasmic domain of gp41 is required for HIV-1 replication and pathogenesis in vivo. Virology (2001) 0.79
Solution structure of calmodulin bound to the binding domain of the HIV-1 matrix protein. J Biol Chem (2014) 0.79
Generation of H9 T-cells stably expressing a membrane-bound form of the cytoplasmic tail of the Env-glycoprotein: lack of transcomplementation of defective HIV-1 virions encoding C-terminally truncated Env. Retrovirology (2006) 0.78
Calcium-dependent association of calmodulin with the rubella virus nonstructural protease domain. J Biol Chem (2010) 0.76
Understanding the process of envelope glycoprotein incorporation into virions in simian and feline immunodeficiency viruses. Viruses (2014) 0.76
Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology (1974) 6.53
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
Antiinflammatory properties of HDL. Circ Res (2004) 5.41
Human erythrocyte membrane glycoprotein: a re-evaluation of the molecular weight as determined by SDS polyacrylamide gel electrophoresis. Biochem Biophys Res Commun (1971) 5.18
Isolation of paramyxovirus glycoproteins. Association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein. Virology (1972) 4.05
An electron microscopic study of moderate and virulent virus-cell interactions of the parainfluenza virus SV5. Virology (1966) 4.03
Proteins of vesicular stomatitis virus and of phenotypically mixed vesicular stomatitis virus-simian virus 5 virions. J Virol (1971) 4.02
Influenza virus structural and nonstructural proteins in infected cells and their plasma membranes. Virology (1971) 3.96
Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus: use of this peptide sequence in the synthesis of biologically active peptides. Proc Natl Acad Sci U S A (1989) 3.94
The membrane structure of lipid-containing viruses. Biochim Biophys Acta (1974) 3.92
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol (1995) 3.82
The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res (1992) 3.74
Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol (1976) 3.61
Influenza virus proteins. I. Analysis of polypeptides of the virion and identification of spike glycoproteins. Virology (1970) 3.58
Amphipathic helix motif: classes and properties. Proteins (1990) 3.52
A molecular theory of lipid-protein interactions in the plasma lipoproteins. FEBS Lett (1974) 3.43
Chemical characterization and surface orientation of the major glycoprotein of the human erythrocyte membrane. Proc Natl Acad Sci U S A (1972) 3.27
Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses. J Virol (1992) 3.20
Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A (1991) 3.18
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
Structure of the ribonucleoprotein of influenza virus. J Virol (1972) 3.11
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother (1998) 3.01
Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Semin Cell Dev Biol (1999) 3.01
Surface expression of viral glycoproteins is polarized in epithelial cells infected with recombinant vaccinia viral vectors. EMBO J (1986) 3.00
Assembly of animal viruses at cellular membranes. Annu Rev Microbiol (1988) 2.99
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 2.91
Membrane proteins: amino acid sequence and membrane penetration. J Mol Biol (1974) 2.67
Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res (1980) 2.63
Functional interaction of paramyxovirus glycoproteins: identification of a domain in Sendai virus HN which promotes cell fusion. J Virol (1996) 2.63
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 2.62
Nucleocapsid protein subunits of simian virus 5, Newcastle disease virus, and Sendai virus. J Virol (1970) 2.58
Influenza virus hemagglutinin expression is polarized in cells infected with recombinant SV40 viruses carrying cloned hemagglutinin DNA. Cell (1983) 2.54
Isolation and properties of the helical nucleocapsid of the parainfluenza virus SV5. Proc Natl Acad Sci U S A (1967) 2.46
Major glycoprotein of the human erythrocyte membrane: evidence for an amphipathic molecular structure. Arch Biochem Biophys (1973) 2.44
Proteins and glycoproteins of paramyxoviruses: a comparison of simian virus 5, Newcastle disease virus, and Sendai virus. J Virol (1971) 2.44
The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. Virology (1998) 2.43
The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A (2004) 2.39
Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types. J Virol (1992) 2.36
Location of the glycoprotein in the membrane of Sindbis virus. Nat New Biol (1971) 2.35
Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol (2005) 2.33
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res (2008) 2.27
Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain. Virology (1993) 2.23
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res (2000) 2.22
Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Atherosclerosis (2012) 2.19
Effects of glucosamine, 2-deoxyglucose, and tunicamycin on glycosylation, sulfation, and assembly of influenza viral proteins. Virology (1978) 2.13
Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res (2001) 2.11
Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol (2000) 2.11
Polarity of influenza and vesicular stomatitis virus maturation in MDCK cells: lack of a requirement for glycosylation of viral glycoproteins. Proc Natl Acad Sci U S A (1979) 2.09
MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med (1999) 2.07
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res (2000) 2.05
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain. J Virol (1994) 2.00
D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2005) 1.99
Influenza virus proteins. II. Association with components of the cytoplasm. Virology (1973) 1.98
Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res (2007) 1.96
Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology (1996) 1.95
Concern Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci U S A (2006) 1.92
Basolateral maturation of retroviruses in polarized epithelial cells. J Virol (1983) 1.90
Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem (1985) 1.89
The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem (1994) 1.89
An electron microscopic study of the presence or absence of neuraminic acid in enveloped viruses. Virology (1970) 1.88
Identification of the spike proteins of Rous sarcoma virus. Virology (1971) 1.87
Protection against vaginal SIV transmission with microencapsulated vaccine. Science (1993) 1.86
Phenotypic mixing of envelope proteins of the parainfluenza virus SV5 and vesicular stomatitis virus. J Virol (1970) 1.85
A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J Lipid Res (2000) 1.83
An amphipathic alpha-helix at a membrane interface: a structural study using a novel X-ray diffraction method. J Mol Biol (1999) 1.82
Red cell membrane glycoprotein: amino acid sequence of an intramembranous region. Biochem Biophys Res Commun (1972) 1.80
Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta (2001) 1.80
Host cell dependence of viral morphology. Proc Natl Acad Sci U S A (1998) 1.78
Respiratory syncytial virus matures at the apical surfaces of polarized epithelial cells. J Virol (1995) 1.73
The role of dysfunctional HDL in atherosclerosis. J Lipid Res (2008) 1.73
Murine model for evaluation of protective immunity to influenza virus. Vaccine (1993) 1.73
Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces. J Virol (1997) 1.71
Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A (2010) 1.71
Surface expression of influenza virus neuraminidase, an amino-terminally anchored viral membrane glycoprotein, in polarized epithelial cells. Mol Cell Biol (1985) 1.69
Regulation of the late events in flavivirus protein processing and maturation. Virology (1993) 1.68
Release of simian virus 40 virions from epithelial cells is polarized and occurs without cell lysis. J Virol (1989) 1.66
Association of the membrane-penetrating polypeptide segment of the human erythrocyte MN-glycoprotein with phospholipid bilayers. I. Formation of freeze-etch intramembranous particles. Proc Natl Acad Sci U S A (1974) 1.66
An electron microscopic study of single-cycle infection of chick embryo fibroblasts by influenza virus. Virology (1969) 1.65
The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Proc Natl Acad Sci U S A (1995) 1.65
The P gene of human parainfluenza virus type 1 encodes P and C proteins but not a cysteine-rich V protein. J Virol (1991) 1.64
Parainfluenza virus surface projections: glycoproteins with haemagglutinin and neuraminidase activities. J Gen Virol (1971) 1.62
Mean field stochastic boundary molecular dynamics simulation of a phospholipid in a membrane. Biochemistry (1991) 1.60
Expression of the human immunodeficiency virus envelope glycoprotein is restricted to basolateral surfaces of polarized epithelial cells. J Virol (1989) 1.59
Spin-labeled electron spin resonance study of the lipid-containing membrane of influenza virus. Proc Natl Acad Sci U S A (1971) 1.57
The human immunodeficiency virus type 1 envelope glycoprotein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processing. Virology (1990) 1.57
Host cell- and virus strain-dependent differences in oligosaccharides of hemagglutinin glycoproteins of influenza A viruses. Virology (1979) 1.56
Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly. Arterioscler Thromb Vasc Biol (1996) 1.55
A specific labeling procedure for proteins on the outer surface of membranes. J Biol Chem (1972) 1.55
Computer programs to identify and classify amphipathic alpha helical domains. J Lipid Res (1992) 1.54
Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J Biol Chem (1992) 1.53
A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res (2001) 1.53